Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Executive summary

Conclusions

1 evidence topic · 14 sources

Summary

CIDP affected an estimated 77,058 individuals in the United States in 2023, 78% of patients in one survey had a progressive or relapsing course, and in US claims mean total costs were 7.5 times those of matched controls ($116,330 compared with $15,586), with CIDP therapy accounting for 51.2% of mean total costs among cases. Around a third of patients do not respond to current treatments and approximately two-thirds need long-term intravenous immunoglobulin. For Vyvgart Hytrulo (efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase), approved for CIDP in June 2024, CDA-AMC estimated $1,872,111 per QALY gained for efgartigimod alfa injection compared with immunoglobulin, and NICE draft guidance states that efgartigimod should not be used.

Claseprubart is an investigational monoclonal antibody that selectively inhibits the active form of C1s. The evidence in CIDP consists of an open-label interim analysis of 40 participants in Part A of the phase 3 CAPTIVATE trial, in which 75% were confirmed responders and no treatment-related serious adverse events or serious infections were reported, together with phase 1 data in healthy volunteers. No randomized results, peer-reviewed publication, price, or budget impact model exist. The company believes that CAPTIVATE, as a single pivotal trial, will support a Biologics License Application, with Part B top-line results expected by the end of 2028. The company states that the safety and efficacy of claseprubart have not been evaluated in head-to-head comparative clinical studies.